Top Markets
#1 MowCat MowCat +49.01%
#2 Velvet Velvet +26.59%
#3 Bermuda Shorts Bermuda Shorts +25.72%
#4 Biconomy Biconomy +21.45%
#5 Derive Derive +19.83%
#6 Audiera Audiera +19.36%
#7 Quack AI Quack AI +19.08%
#8 aPriori aPriori +18.64%
#9 Geodnet Geodnet +12.02%
#10 DODO DODO +11.93%
Coin of the day
MowCat MowCat
Settings
Language
ENGLISH
Currency
USD
Theme
IMV Inc. IMV Inc.

IMV Inc.

IMV
Rank in Stocks #35289
IMV Inc. is a clinical-stage biotechnology company dedicated to the development... IMV Inc. is a clinical-stage biotechnology company dedicated to the development of innovative immunotherapies. The company utilizes its proprietary DPX immune-educating technology platform to create a portfolio of treatments for various solid and hematological cancers. Its leading investigational drug, maveropepimut-S, is a DPX-based immunotherapy designed to target cancer cells that express survivin. Maveropepimut-S is currently undergoing Phase II clinical trials for diffuse large B-cell lymphoma, ovarian cancer, and specific bladder, liver, and microsatellite instability-high tumors, with Phase I trials also active for breast cancer. Beyond its primary candidate, IMV is also advancing DPX-SurMAGE, which is in Phase I clinical trials for bladder cancer, and is developing DPX-COVID-19 and DPX-RSV to address infectious diseases. Originally founded in 2000 as Immunovaccine Inc., the company adopted the name IMV Inc. in May 2018 and operates from its headquarters in Dartmouth, Canada.
Share Price
$0.82959892
Last synced: 2023-05-23
Market Cap
$4.16M
Change (1 day)
-0.04%
Change (1 year)
0.00%
Country
CA
Trade IMV Inc. (IMV)

Category

Healthcare
Earnings for IMV Inc. (IMV)
Earnings in 2026 TTM: 0
According to IMV Inc. latest financial reports the company's current earnings are 0. In 2026 the company made an earning of 0, equal to its 2026 earnings that were of 0. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for IMV Inc. from 2026 to 2026
Earnings at the end of each year
Year Earnings Change
Not enough data for the provided dates.
Earnings for similar companies or competitors
Company Earnings Earnings Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE